[1] Yi EJ, Shin YJ, Kim JH, et al. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res, 2017; 6, 4-14. doi:  10.7774/cevr.2017.6.1.4
[2] National Health and Family Planning Commision of the PRC. The epidemic situation of national notifiable infectious diseases. http://www.nhfpc.gov.cn/jkj/s3578/new_list.shtml. [2018-01-11]
[3] Shigui Y, Jie W, Cheng D, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak:an observational trend study. Lancet Infect Dis, 2017; 17, 716-25. doi:  10.1016/S1473-3099(17)30227-X
[4] Yang F, Yuan J, Wang X, et al. Severe hand, foot, and mouth disease and coxsackievirus A6-Shenzhen, China. Clin Infect Dis, 2014; 59, 1504-5. doi:  10.1093/cid/ciu624
[5] Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis, 2010; 10, 778-90. doi:  10.1016/S1473-3099(10)70194-8
[6] Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol, 2012; 19, 424-9. doi:  10.1038/nsmb.2255
[7] Huang SW, Cheng HL, Hsieh HY, et al. Mutations in the non-structural protein region contribute to intra-genotypic evolution of enterovirus 71. J Biomed Sci, 2014; 21, 33. doi:  10.1186/1423-0127-21-33
[8] Foo DG, Alonso S, Phoon MC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res, 2007; 125, 61-8. doi:  10.1016/j.virusres.2006.12.005
[9] Dudek NL, Perlmutter P, Aguilar MI, et al. Epitope discovery and their use in peptide based vaccines. Curr Pharm Des, 2010; 16, 3149 -57. doi:  10.2174/138161210793292447
[10] Bachmann MF, Jennings GT. Vaccine Delivery:A Matter of Size, Geometry, Kinetics and Molecular Patterns. Nat Rev Immunol, 2010; 10, 787-96. doi:  10.1038/nri2868
[11] Brune KD, Leneghan DB, Brian IJ, et al. Plug-and-Display:decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep, 2016; 6, 19234. doi:  10.1038/srep19234
[12] Thrane S, Janitzek CM, Agerbæk M, et al. A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One, 2015; 10, e0143071. doi:  10.1371/journal.pone.0143071
[13] Koho T, Ihalainen TO, Stark M, et al. His-tagged norovirus-like particles:A versatile platform for cellular delivery and surface display. Eur J Pharm Biopharm, 2015; 96, 22-31. doi:  10.1016/j.ejpb.2015.07.002
[14] Frietze KM, Peabody DS, Chackerian B. Engineering virus-like particles as vaccine platforms. Curr Opin Virol, 2016; 18, 44-9. doi:  10.1016/j.coviro.2016.03.001
[15] Plummer EM, Manchester M. Viral Nanoparticles and Virus-Like Particles:Platforms for Contemporary Vaccine Design. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2011; 3, 174-96. doi:  10.1002/wnan.119
[16] Pumpens P, Grens E. HBV Core Particles as a Carrier for B Cell/T Cell Epitopes. Intervirology, 2011; 44, 98-114. https://www.researchgate.net/profile/Paul_Pumpens/publication/11835266_HBV_Core_Particles_as_a_Carrier_for_B_CellT_Cell_Epitopes/links/54e4a48c0cf29865c334b33b.pdf?origin=publication_list
[17] Fan P, Li X, Sun S, et al. Identification of a Common Epitope between Enterovirus 71 and Human MED25 Proteins Which May Explain Virus-Associated Neurological Disease. Viruses, 2015; 7, 1558-77. doi:  10.3390/v7041558
[18] Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS):toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res, 2013; 56, 304-16. doi:  10.1007/s12026-013-8403-1
[19] Cao L, Mao F, Pang Z, et al. Protective effect of enterovirus-71 (EV71) virus-like particle vaccine against lethal EV71 infection in a neonatal mouse model. Mol Med Rep, 2015; 12, 2473-80. doi:  10.3892/mmr.2015.3680
[20] Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre-and post-attachment steps. PLoS One, 2013; 8, e57601. doi:  10.1371/journal.pone.0057601
[21] Ye X, Ku Z, Liu Q, et al. Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms. J Virol, 2014; 88, 72-81. doi:  10.1128/JVI.01848-13
[22] Majorek KA, Kuhn ML, Chruszcz M, et al. Double trouble-buffer selection and His-tag presence may be responsible for nonreproducibility of biomedical experiments. Protein Sci, 2014; 23, 1359-68. doi:  10.1002/pro.v23.10
[23] Zhao X, Zhang H, Liu Y, et al. Preparation of monoclonal antibodies against His-tag and epitope analysis of cross antigens. Chin J Cell Mol Immunol, 2016; 32, 683-7. (In Chinese) http://europepmc.org/abstract/med/27126949
[24] Sedlik C. Thl and Th2 subsets of T lymphocytes:Characteristics, physiological role and regulation. Bull Inst Pasteur, 1996; 94, 173-200. doi:  10.1016/S0020-2452(97)86016-2
[25] Mosmann TR, Sad S. The expanding universe of T-cells subsets:Thl, Th2 and more. Immunol Today, 1996; 17, 138-46. doi:  10.1016/0167-5699(96)80606-2
[26] Debin A, Kravtzoff R, Santiago JV, et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine, 2002; 20, 2752-63. doi:  10.1016/S0264-410X(02)00191-3
[27] Cao RY, Dong DY, Liu RJ, et al. Human IgG subclasses against enterovirus Type 71:neutralization versus antibody dependent enhancement of infection. PLoS One, 2013; 8, e64024. doi:  10.1371/journal.pone.0064024
[28] Guo F, Zhao Q, Sheraz M, et al. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. Plos Pathogens, 2017; 13, e1006658. doi:  10.1371/journal.ppat.1006658
[29] Akbar SM, Chen S, Almahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B:HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res, 2012; 96, 59-64. doi:  10.1016/j.antiviral.2012.07.011
[30] Xu L, He D, Yang L, et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci Rep, 2015; 5, 12973. doi:  10.1038/srep12973